Publications & References -

Genetic interventions in mammalian cells; applications and uses in high-throughput screening and drug discovery.
Hampton SL, Kinnaird AI.. Genetic interventions in mammalian cells; applications and uses in high-throughput screening and drug discovery.. Cell Biol Toxicol. 2010 Feb;26(1):43-55. Epub 2009 Nov 11.. PMID:19904619
Chemical validation of phosphodiesterase C as a chemotherapeutic target in Trypanosoma cruzi, the etiological agent of Chagas' disease.
King-Keller S, Li M, Smith A, Zheng S, Kaur G, Yang X, Wang B, Docampo R.. Chemical validation of phosphodiesterase C as a chemotherapeutic target in Trypanosoma cruzi, the etiological agent of Chagas' disease.. Antimicrob Agents Chemother. 2010 Sep;54(9):3738-45. Epub 2010 Jul 12.. PMID:20625148
Distinct metabolism of cyclic adenosine monophosphate in regulatory and helper CD4+ T cells.
Bazhin AV, Kahnert S, Kimpfler S, Schadendorf D, Umansky V.. Distinct metabolism of cyclic adenosine monophosphate in regulatory and helper CD4+ T cells.. Mol Immunol. 2010 Jan;47(4):678-84. Epub 2009 Nov 24.. PMID:19939455
The molecular basis of species-specific ligand activation of trace amine-associated receptor 1 (TAAR(1)).
Tan ES, Naylor JC, Groban ES, Bunzow JR, Jacobson MP, Grandy DK, Scanlan TS.. The molecular basis of species-specific ligand activation of trace amine-associated receptor 1 (TAAR(1)).. ACS Chem Biol. 2009 Mar 20;4(3):209-20.. PMID:19256523
GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility.
Sanger GJ, Westaway SM, Barnes AA, Macpherson DT, Muir AI, Jarvie EM, Bolton VN, Cellek S, Näslund E, Hellström PM, Borman RA, Unsworth WP, Matthews KL, Lee K.. GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility.. Neurogastroenterol Motil. 2009 Jun;21(6):657-64, e30-1.. PMID:19374732
The effect of assay formats on the estimation of melanocortin agonist affinity and efficacy using the operation model of agonism.
Simon S, Young TJ, Nickolls SA.. The effect of assay formats on the estimation of melanocortin agonist affinity and efficacy using the operation model of agonism.. Eur J Pharmacol. 2009 Aug 1;615(1-3):33-9. Epub 2009 May 14.. PMID:19446549
Pharmacology of a novel, orally active PDE4 inhibitor.
Dastidar SG, Ray A, Shirumalla R, Rajagopal D, Chaudhary S, Nanda K, Sharma P, Seth MK, Balachandran S, Gupta N, Palle V.. Pharmacology of a novel, orally active PDE4 inhibitor.. Pharmacology. 2009;83(5):275-86. Epub 2009 Mar 25.. PMID:19321962
Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist.
Griffith DA, Hadcock JR, Black SC, Iredale PA, Carpino PA, DaSilva-Jardine P, Day R, DiBrino J, Dow RL, Landis MS, O'Connor RE, Scott DO.. Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist.. J Med Chem. 2009 Jan 22;52(2):234-7.. PMID:19102698
RXFP1-inactive relaxin activates human glucocorticoid receptor: further investigations into the relaxin-GR pathway.
Dschietzig T, Bartsch C, Baumann G, Stangl K.. RXFP1-inactive relaxin activates human glucocorticoid receptor: further investigations into the relaxin-GR pathway.. Regul Pept. 2009 Apr 10;154(1-3):77-84. Epub 2008 Dec 7.. PMID:19101597
Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists.
Heinrich JN, Butera JA, Carrick T, Kramer A, Kowal D, Lock T, Marquis KL, Pausch MH, Popiolek M, Sun SC, Tseng E, Uveges AJ, Mayer SC.. Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists.. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6. Epub 2009 Jan 11.. PMID:19168056
Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models.
Prasanna G, Fortner J, Xiang C, Zhang E, Carreiro S, Anderson S, Sartnurak S, Wu G, Gukasyan H, Niesman M, Nair S, Rui E, Lafontaine J, Almaden CD, Wells P, Krauss A.. Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models.. Exp Eye Res. 2009 Nov;89(5):608-17. Epub 2009 May 13.. PMID:19445930
Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.
Roncarati R, Scali C, Comery TA, Grauer SM, Aschmi S, Bothmann H, Jow B, Kowal D, Gianfriddo M, Kelley C, Zanelli U, Ghiron C, Haydar S, Dunlop J, Terstappen GC.. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.. J Pharmacol Exp Ther. 2009 May;329(2):459-68. Epub 2009 Feb 17.. PMID:19223665
Identification of surrogate agonists and antagonists for orphan G-protein-coupled receptor GPR139.
Hu LA, Tang PM, Eslahi NK, Zhou T, Barbosa J, Liu Q.. Identification of surrogate agonists and antagonists for orphan G-protein-coupled receptor GPR139.. J Biomol Screen. 2009 Aug;14(7):789-97. Epub 2009 Jun 12.. PMID:19525486
a-Hederin, but Not Hederacoside C and Hederagenin from Hedera helix, Affects the Binding Behavior, Dynamics, and Regulation of ß2-Adrenergic Receptors
Anne Sieben, Lars Prenner, Thomas Sorkalla, Anne Wolf, Daniel Jakobs, Frank Runkel, Hanns Haberlein. a-Hederin, but Not Hederacoside C and Hederagenin from Hedera helix, Affects the Binding Behavior, Dynamics, and Regulation of ß2-Adrenergic Receptors. Biochemistry, 2009, 48 (15), pp 3477–3482. DOI:10.1021/bi802036b
Constitutive activity of cannabinoid-2 (CB2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242.
Mancini I, Brusa R, Quadrato G, Foglia C, Scandroglio P, Silverman LS, Tulshian D, Reggiani A, Beltramo M.. Constitutive activity of cannabinoid-2 (CB2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242.. Br J Pharmacol. 2009 Sep;158(1):382-91. Epub 2009 Jun 22.. PMID:19552692
Activation of relaxin-related receptors by short, linear peptides derived from a collagen-containing precursor.
Shemesh R, Hermesh C, Toporik A, Levine Z, Novik A, Wool A, Kliger Y, Rosenberg A, Bathgate RA, Cohen Y.. Activation of relaxin-related receptors by short, linear peptides derived from a collagen-containing precursor.. Ann N Y Acad Sci. 2009 Apr;1160:78-86.. PMID:19416163
Peripheral and central sites of action for the non-selective cannabinoid agonist WIN 55,212-2 in a rat model of post-operative pain.
Zhu CZ, Mikusa JP, Fan Y, Hollingsworth PR, Pai M, Chandran P, Daza AV, Yao BB, Dart MJ, Meyer MD, Decker MW, Hsieh GC, Honore P.. Peripheral and central sites of action for the non-selective cannabinoid agonist WIN 55,212-2 in a rat model of post-operative pain.. Br J Pharmacol. 2009 Jun;157(4):645-55. Epub 2009 Apr 3.. PMID:19371344
Up-regulation of AGS3 during morphine withdrawal promotes cAMP superactivation via adenylyl cyclase 5 and 7 in rat nucleus accumbens/striatal neurons.
Fan P, Jiang Z, Diamond I, Yao L.. Up-regulation of AGS3 during morphine withdrawal promotes cAMP superactivation via adenylyl cyclase 5 and 7 in rat nucleus accumbens/striatal neurons.. Mol Pharmacol. 2009 Sep;76(3):526-33. Epub 2009 Jun 23.. PMID:19549762
Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo.
Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL.. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo.. Psychopharmacology (Berl). 2009 Jul;205(1):119-28. Epub 2009 Apr 1.. PMID:19337725
Use of the DiscoverX Hit hunter cAMPII assay for direct measurement of cAMP in Gs and Gi GPCRs.
Bradley J, McLoughlin D. Use of the DiscoverX Hit hunter cAMPII assay for direct measurement of cAMP in Gs and Gi GPCRs. Methods Mol Biol. 2009;552:171-9. PMID:19513649

Displaying results 281-300 (of 401)

|< < 11 12 13 14 15 16 17 18 19 20 > >|

Characterizing cannabinoid CB2 receptor ligands using DiscoverX PathHunter beta-arrestin assay.
McGuinness D, Malikzay A, Visconti R, Lin K, Bayne M, Monsma F, Lunn CA. Characterizing cannabinoid CB2 receptor ligands using DiscoveRx PathHunter beta-arrestin assay. J Biomol Screen. 2009 Jan;14(1):49-58. PMID:19171920
Pharmacological characterization of receptor redistribution and beta-arrestin recruitment assays for the cannabinoid receptor 1.
van der Lee MM, Blomenröhr M, van der Doelen AA, Wat JW, Smits N, Hanson BJ, van Koppen CJ, Zaman GJ. Pharmacological characterization of receptor redistribution and beta-arrestin recruitment assays for the cannabinoid receptor 1. J Biomol Screen 14(7):811-23. PMID:19520790
Using ligand-induced conformational change to screen for compounds targeting G-protein-coupled receptors.
O'Dowd BF, Alijaniaram M, Ji X, Nguyen T, Eglen RM, George SR.. Using ligand-induced conformational change to screen for compounds targeting G-protein-coupled receptors.. J Biomol Screen. 2007 Mar;12(2):175-85. Epub 2007 Feb 8.. PMID:17289935
GATA4 expression is primarily regulated via a miR-26b-dependent post-transcriptional mechanism during cardiac hypertrophy.
Han M, Yang Z, Sayed D, He M, Gao S, Lin L, Yoon S, Abdellatif M.. GATA4 expression is primarily regulated via a miR-26b-dependent post-transcriptional mechanism during cardiac hypertrophy.. Cardiovasc Res, Mar 2012; 93: 645 - 654.. PMID:22219180
Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay.
Yin H, Chu A, Li W, Wang B, Shelton F, Otero F, Nguyen DG, Caldwell JS and Chen YA. Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem 284(18):12328-38. PMID:19286662
A homogeneous enzyme fragment complementation-based beta-arrestin translocation assay for high-throughput screening of G-protein-coupled receptors.
Zhao X, Jones A, Olson KR, Peng K, Wehrman T, Park A, Mallari R, Nebalasca D, Young SW and Xiao SH. A homogeneous enzyme fragment complementation-based beta-arrestin translocation assay for high-throughput screening of G-protein-coupled receptors. J Biomol Screen 13(8):737-47. PMID:18660457
C5a-stimulated recruitment of beta-arrestin2 to the nonsignaling 7-transmembrane decoy receptor C5L2.
Van Lith LH, Oosterom J, Van Elsas A, Zaman GJ. C5a-stimulated recruitment of beta-arrestin2 to the nonsignaling 7-transmembrane decoy receptor C5L2.. J Biomol Screen. 2009 Oct;14(9):1067-75. Epub 2009 Jul 29.. PMID:19641221

Displaying results 181-187 (of 187)

|< < 1 2 3 4 5 6 7 8 9 10 > >|

A Potent, Selective and Cell-Active Allosteric Inhibitor of Protein Arginine Methyltransferase 3 (PRMT3)
Kaniskan HÜ1, Szewczyk MM, Yu Z, Eram MS, Yang X, Schmidt K, Luo X, Dai M, He F, Zang I, Lin Y,Kennedy S, Li F, Dobrovetsky E, Dong A, Smil D, Min SJ, Landon M, Lin-Jones J, Huang XP, Roth BL,Schapira M, Atadja P, Barsyte-Lovejoy D, Arrowsmith CH, Brown PJ, Zhao K, Jin J, Vedadi M. A Potent, Selective and Cell-Active Allosteric Inhibitor of Protein Arginine Methyltransferase 3 (PRMT3). Angew Chem Int Ed Engl. 2015 Apr 20;54(17):5166-70. doi: 10.1002/anie.201412154. Epub 2015 Feb 27. PMID:25728001
Cell-based protein stabilization assays for the detection of interactions between small-molecule inhibitors and BRD4.
Schulze J, Moosmayer D, Weiske J, Fernández-Montalván A, Herbst C, Jung M, Haendler B, Bader B. Cell-based protein stabilization assays for the detection of interactions between small-molecule inhibitors and BRD4. J Biomol Screen. 2015 Feb;20(2):180-9. doi: 10.1177/1087057114552398. Epub 2014 Sep 29. PMID:25266565

A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors
Celeste Romero , Lester J. Lambert , Douglas J. Sheffler , Laurent J.S. De Backer , Dhanya RaveendraPanickar , Maria Celeridad , Stefan Grotegut , Socorro Rodiles , John Holleran , Eduard Sergienko , Elena B. Pasquale3 , Nicholas D. P. Cosford , and Lutz Tautz. A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors
Sorafenib activity and disposition in liver cancer does not depend on organic cation transporter 1 (OCT1).
Chen M, Neul C, Schaeffeler E, Frisch F, Winter S, Schwab M, Koepsell H, Hu S, Laufer S, Baker SD, Sparreboom A, Nies AT. Clin Pharmacol Ther. 2019 Jul 27
Activation of TrkB with TAM-163 results in opposite effects on body weight in rodents and non-human primates.
Perreault M, Feng G, Will S, Gareski T, Kubasiak D, Marquette K, Vugmeyster Y, Unger TJ, Jones J, Qadri A, Hahm S, Sun Y, Rohde CM, Zwijnenberg R, Paulsen J, Gimeno RE. Activation of TrkB with TAM-163 results in opposite effects on body weight in rodents and non-human primates. PLoS One. 2013 May 20;8(5):e62616. PMID:23700410
Development of Three Orthogonal Assays Suitable for the Identification and Qualification of PIKfyve Inhibitors.
Fogarty K, Kashem M, Bauer A, Bernardino A, Brennan D, Cook B, Farrow N, Molinaro T, Nelson R. Development of Three Orthogonal Assays Suitable for the Identification and Qualification of PIKfyve Inhibitors. Assay Drug Dev Technol. 2017 Jul;15(5):210-219. PMID:28723271
A High-Throughput Dose-Response Cellular Thermal Shift Assay for Rapid Screening of Drug Target Engagement in Living Cells, Exemplified Using SMYD3 and IDO1
McNulty DE, Bonnette WG, Qi H, Wang L, Ho TF, Waszkiewicz A, Kallal LA, Nagarajan RP, Stern M, Quinn AM, Creasy CL, Su DS, Graves AP, Annan RS, Sweitzer SM, Holbert MA. A High-Throughput Dose-Response Cellular Thermal Shift Assay for Rapid Screening of Drug Target Engagement in Living Cells, Exemplified Using SMYD1 and IDO1. SLAS Discov. 2017 Sep;1:2472555217732014. PMID:28957646
Structural characterization of nonactive site, TrkA-selective kinase inhibitors
Su HP1, Rickert K2, Burlein C3, Narayan K3, Bukhtiyarova M3, Hurzy DM4, Stump CA4, Zhang X4, Reid J4, Krasowska-Zoladek A5, Tummala S2, Shipman JM2, Kornienko M2, Lemaire PA3, Krosky D2, Heller A3, Achab A6, Chamberlin C6, Saradjian P6, Sauvagnat B6, Yang X6, Ziebell MR6, Nickbarg E6, Sanders JM4, Bilodeau MT4, Carroll SS3, Lumb KJ2, Soisson SM4, Henze DA5, Cooke AJ4. Structural characterization of nonactive site, TrkA-selective kinase inhibitors. Proc Natl Acad Sci U S A. 2017 Jan 17; 114 (3): E297-E306.
Multiplex quantitative assays indicate a need for reevaluating reported small-molecule TrkB agonists
Boltaev U1,2, Meyer Y1, Tolibzoda F1,2, Jacques T1, Gassaway M1,2, Xu Q3, Wagner F3, Zhang YL3, Palmer M3, Holson E3, Sames D4,2.. Multiplex quantitative assays indicate a need for reevaluating reported small-molecule TrkB agonists. Sci Signal. 2017 Aug 22; 10 (493).
Design, synthesis and SAR of substituted indoles as selective TrkA inhibitors.
Hurzy DM1, Henze DA2, Cabalu TD3, Narayan K4, Heller A5, Cooke AJ6. Design, synthesis and SAR of substituted indoles as selective TrkA inhibitors. Bioorg Med Chem Lett. 2017 Jun 15; 27 (12): 2695-2701.
Small-Molecule Target Engagement in Cells.
Schürmann M, Janning P, Ziegler S, Waldmann H. Small-Molecule Target Engagement in Cells. Cell Chem Biol. 2016 Apr 21;23(4):435-41. doi:10.1016/j.chembiol.2016.03.008. Epub 2016 Mar 31. PMID:27049669
Examining Ligand-Based Stabilization of Proteins in Cells with MEK1 Kinase Inhibitors.
Auld DS, Davis CA, Jimenez M, Knight S, Orme JP. Examining Ligand-Based Stabilization of Proteins in Cells with MEK1 Kinase Inhibitors. Assay Drug Dev Technol. 2015 Jun;13(5):266-76. PMID:26107610
Discovery of MINC1, a GTPase-Activating Protein Small Molecule Inhibitor, Targeting MgcRacGAP
van Adrichem AJ, Fagerholm A, Turunen L, Lehto A, Saarela J, Koskinen A, Repasky GA, Wennerberg K. Discovery of MINC1, a GTPase-Activating Protein Small Molecule Inhibitor, Targeting MgcRacGAP. Comb Chem High Throughput Screen. 2015;18(1):3-17. PMID:25479424
The Use of TrkA-PathHunter Assay in High-Throughput Screening to identify Compounds That Affect Nerve Growth Factor Signaling.
Forsell P, Almqvist H, Hillertz P, Akerud T, Otrocka M, Eisele L, Sun K, Andersson H, Trivedi S, Wollberg AR, Dekker N, Rottici D, Sandberg K. The Use of TrkA-PathHunter Assay in High-Throughput Screening to Identify Compounds That Affect Nerve Growth Factor Signaling. J Biomol Screen. 2013 Mar 4. PMID:19940259
Development of a Highly Selective c-Src Kinase Inhibitor
Kristoffer R. Brandvold, Michael E. Steffey, Christel C. Fox, and Matthew B. Soellner. Development of a Highly Selective c-Src Kinase Inhibitor. ACS Chem Biol. 2012 Aug 17;7(8):1393-8. Epub 2012 Jun 4. PMID:22594480
Comprehensive analysis of kinase inhibitor selectivity
Mindy I Davis, Jeremy P Hunt, Sanna Herrgard, Pietro Ciceri, Lisa M Wodicka, Gabriel Pallares, Michael Hocker, Daniel K Treiber & Patrick P Zarrinkar. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51. doi: 10.1038/nbt.1990.. PMID:22037378
Trends in kinase selectivity: insights for target class-focused library screening.
Posy SL, Hermsmeier MA, Vaccaro W, Ott KH, Todderud G, Lippy JS, Trainor GL, Loughney DA, Johnson SR.. Trends in kinase selectivity: insights for target class-focused library screening.. J Med Chem. 2011 Jan 13;54(1):54-66. Epub 2010 Dec 3.. PMID:21128601
Why do kinase inhibitors cause cardiotoxicity and what can be done about it?
Cheng H, Force T.. Why do kinase inhibitors cause cardiotoxicity and what can be done about it?. Prog Cardiovasc Dis. 2010 Sep-Oct;53(2):114-20.. PMID:20728698
Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function.
Kwiatkowski N, Jelluma N, Filippakopoulos P, Soundararajan M, Manak MS, Kwon M, Choi HG, Sim T, Deveraux QL, Rottmann S, Pellman D, Shah JV, Kops GJ, Knapp S, Gray NS.. Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function.. Nat Chem Biol. 2010 May;6(5):359-68. Epub 2010 Apr 11.. PMID:20383151
Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase.
Milkiewicz KL, Weinberg LR, Albom MS, Angeles TS, Cheng M, Ghose AK, Roemmele RC, Theroff JP, Underiner TL, Zificsak CA, Dorsey BD.. Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase.. Bioorg Med Chem. 2010 Jun 15;18(12):4351-62. Epub 2010 Apr 29.. PMID:20483621
Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development.
Goldstein DM, Gabriel T.. Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development.. Curr Top Med Chem. 2005;5(10):1017-29.. PMID:16178744

Discovery of Benzimidazole Oxazolidinediones as Novel and Selective Nonsteroidal Mineralocorticoid Receptor Antagonists
Christine Yang, Jaume Balsells, Hong D. Chu, Jason M. Cox, Alejandro Crespo, Xiuying Ma, Lisa Contino, Patricia Brown, Sheng Gao, Beata Zamlynny, Judyann Wiltsie, Joseph Clemas, JeanMarie Lisnock, Jack Gibson, Gaochao Zhou, Margarita Garcia-Calvo, Thomas J. Bateman, Vincent Tong, Ling Xu, Martin Crook, Peter Sinclair, Hong C. Shen. Discovery of Benzimidazole Oxazolidinediones as Novel and Selective Nonsteroidal Mineralocorticoid Receptor Antagonists. ACS Med. Chem. Lett., 2015, 6 (4), pp 461–465. 10.1021/acsmedchemlett.5b00010
Discovery of a novel isoxazoline derivative of prednisolone endowed with a robust anti-inflammatory profile and suitable for topical pulmonary administration.
Ghidini E, Capelli AM, Carnini C, Cenacchi V, Marchini G, Virdis A, Italia A, Facchinetti F. Discovery of a novel isoxazoline derivative of prednisolone endowed with a robust anti-inflammatory profile and suitable for topical pulmonary administration. Steroids. 2015 Mar;95:88-95. doi: 10.1016/j.steroids.2014.12.016. Epub 2014 Dec 31. PMID:25556984
The translational efficacy of a nonsteroidal progesterone receptor antagonist, 4-[3-cyclopropyl-1-(mesylmethyl)-5-methyl-1H-pyrazol-4-yl]oxy,-2,6-dimethylbenzonitrile (PF-02413873), on endometrial growth in macaque and human.
Howe DC, Mount NM, Bess K, Brown A, Bungay P, Gibson KR, Hawcock T, Richard J, Jones G, Walley R, McLeod A, Apfeldorfer C, Ramsey S, Tweedy S, Pullen N.. The translational efficacy of a nonsteroidal progesterone receptor antagonist, 4-[3-cyclopropyl-1-(mesylmethyl)-5-methyl-1H-pyrazol-4-yl]oxy,-2,6-dimethylbenzonitrile (PF-02413873), on endometrial growth in macaque and human.. J Pharmacol Exp Ther. 2011 Nov;339(2):642-53. Epub 2011 Aug 17.. PMID:21849626
Acute inhibition of 11beta-hydroxysteroid dehydrogenase type-1 improves memory in rodent models of cognition.
Mohler EG, Browman KE, Roderwald VA, Cronin EA, Markosyan S, Scott Bitner R, Strakhova MI, Drescher KU, Hornberger W, Rohde JJ, Brune ME, Jacobson PB, Rueter LE.. Acute inhibition of 11beta-hydroxysteroid dehydrogenase type-1 improves memory in rodent models of cognition.. J Neurosci. 2011 Apr 6;31(14):5406-13.. PMID:21471376
Resveratrol modulates the expression of PTGS2 and cellular proliferation in the normal rat endometrium in an AKT-dependent manner.
Singh M, Parent S, Leblanc V, Asselin E.. Resveratrol modulates the expression of PTGS2 and cellular proliferation in the normal rat endometrium in an AKT-dependent manner.. Biol Reprod. 2011 May;84(5):1045-52. Epub 2011 Jan 19.. PMID:21248286
Cleavage of zearalenone by Trichosporon mycotoxinivorans to a novel nonestrogenic metabolite.
Vekiru E, Hametner C, Mitterbauer R, Rechthaler J, Adam G, Schatzmayr G, Krska R, Schuhmacher R.. Cleavage of zearalenone by Trichosporon mycotoxinivorans to a novel nonestrogenic metabolite.. Appl Environ Microbiol. 2010 Apr;76(7):2353-9. Epub 2010 Jan 29.. PMID:20118365
Expression of Human Nuclear Receptors in Plants for the Discovery of Plant-Derived Ligands.
Doukhanina EV, Apuya NR, Yoo HD, Wu CY, Davidow P, Krueger S, Flavell RB, Hamilton R, Bobzin SC.. Expression of Human Nuclear Receptors in Plants for the Discovery of Plant-Derived Ligands.. J Biomol Screen. 2007 Apr;12(3):385-95.. PMID:17438068

Active participation of cellular chaperone Hsp90 in regulating the function of rotavirus nonstructural protein 3 (NSP3).
Dutta D, Chattopadhyay S, Bagchi P, Halder UC, Nandi S, Mukherjee A, Kobayashi N, Taniguchi K, Chawla-Sarkar M.. Active participation of cellular chaperone Hsp90 in regulating the function of rotavirus nonstructural protein 3 (NSP3).. J Biol Chem. 2011 Jun 3;286(22):20065-77. Epub 2011 Apr 13.. PMID:21489987
Beta-Galactosidase enzyme fragment complementation for the measurement of Wnt/beta-catenin signaling
Verkaar F, van der Stelt M, Blankesteijn WM, van der Doelen AA, Zaman GJ. Beta-Galactosidase enzyme fragment complementation for the measurement of Wnt/beta-catenin signaling. FASEB J. 2010 Apr;24(4):1205-17. PMID:19940259

Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans.
Smith SH, Jayawickreme C, Rickard DJ, Nicodeme E, Bui T, Simmons C, Coquery CM, Neil J, Pryor WM, Mayhew D, Rajpal DK, Creech K, Furst S, Lee J, Wu D, Rastinejad F, Willson TM, Viviani F, Morris DC, Moore JT, Cote-Sierra J. Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans. J Invest Dermatol. 2017;137(10):2110-2119.
A Next-Generation Risk Assessment Case Study for Coumarin in Cosmetic Products
Baltazar MT, Cable S, Carmichael PL, Cubberley R, Cull T, Delagrange M, Dent MP, Hatherell S, Houghton J, Kukic P, Li H, Lee M-Y, Malcomber S, Middleton AM, Moxon TE, Nathanail AV, Nicol B, Pendlington R, Reynolds G, Reynolds J, White A, Westmoreland C. A Next-Generation Risk Assessment Case Study for Coumarin in Cosmetic Products. Toxicol Sci. 2020;176(1):236-252.
Btk inhibition treats TLR7/IFN driven murine lupus
Bender AT, Pereira A, Fu K, Samy E, Wu Y, Liu-Bujalski L, Caldwell R, Chen Y-Y, Tian H, Morandi F, Head J, Koehler U, Genest M, Okitsu SL, Xu D, Grenningloh R. Btk inhibition treats TLR7/IFN driven murine lupus. Clinical Immunology. 2016;164:65-77.
Development of a Topical Treatment for Psoriasis Targeting RORγ: From Bench to Skin.
Smith SH, Peredo CE, Takeda Y, Bui T, Neil J, Rickard D, Millerman E, Therrien J-P, Nicodeme E, Brusq J-M, Birault V, Viviani F, Hofland H, Jetten AM, Cote-Sierra J. Development of a Topical Treatment for Psoriasis Targeting RORγ: From Bench to Skin. PLOS ONE. 2016;11(2):e0147979.
Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.
Betts BC, Bastian D, Iamsawat S, Nguyen H, Heinrichs JL, Wu Y, Daenthanasanmak A, Veerapathran A, O’Mahony A, Walton K, Reff J, Horna P, Sagatys EM, Lee MC, Singer J, Chang Y-J, Liu C, Pidala J, Anasetti C, Yu X-Z. Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. PNAS. 2018;115(7):1582-1587.
The activities of drug inactive ingredients on biological targets.
Pottel J, Armstrong D, Zou L, Fekete A, Huang X-P, Torosyan H, Bednarczyk D, Whitebread S, Bhhatarai B, Liang G, Jin H, Ghaemi SN, Slocum S, Lukacs KV, Irwin JJ, Berg EL, Giacomini KM, Roth BL, Shoichet BK, Urban L. The activities of drug inactive ingredients on biological targets. Science. 2020;369(6502):403-413.
Application of a phenotypic drug discovery strategy to identify biological and chemical starting points for inhibition of TSLP production in lung epithelial cells.
Orellana A, García-González V, López R, Pascual-Guiral S, Lozoya E, Díaz J, Casals D, Barrena A, Paris S, Andrés M, Segarra V, Vilella D, Malhotra R, Eastwood P, Planagumà A, Miralpeix M, Nueda A. Application of a phenotypic drug discovery strategy to identify biological and chemical starting points for inhibition of TSLP production in lung epithelial cells. PLOS ONE. 2018;13(1):e0189247.
Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Interactions with Synaptic Vesicle 2 Proteins and the GABAA Receptor.
Wood M, Daniels V, Provins L, Wolff C, Kaminski RM, Gillard M. Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Interactions with Synaptic Vesicle 2 Proteins and the GABAA Receptor. J Pharmacol Exp Ther. 2020;372(1):1-10.
Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition.
Berg EL. Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition. Front Big Data. 2019;2. doi:10.3389/fdata.2019.00047.
Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
Singer JW, Al-Fayoumi S, Taylor J, Velichko S, O’Mahony A. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures. PLOS ONE. 2019;14(9):e0222944.
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
Haselmayer P, Camps M, Liu-Bujalski L, Nguyen N, Morandi F, Head J, O’Mahony A, Zimmerli SC, Bruns L, Bender AT, Schroeder P, Grenningloh R. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models. The Journal of Immunology. 2019 Apr 15; ji1800583.
Advancing nonclinical innovation and safety in pharmaceutical testing.
Baker EJ, Beck NA, Berg EL, Clayton-Jeter HD, Chandrasekera PC, Curley JL, Donzanti BA, Ewart LC, Gunther JM, Kenna JG, LeCluyse EL, Liebman MN, Pugh CL, Watkins PB, Sullivan KM. Advancing nonclinical innovation and safety in pharmaceutical testing. Drug Discovery Today. 2019;24(2):624–628.
Rational discovery of dual-action multi-target kinase inhibitor for precision anti-cancer therapy using structural systems pharmacology.
Xie L, Lim H, He D, Qiu Y, Krawczuk P, Sun X. Rational discovery of dual-action multi-target kinase inhibitor for precision anti-cancer therapy using structural systems pharmacology. bioRxiv. 2018 Nov 7 [accessed 2019 Mar 21]:465054.
Predictive gene signatures determine tumor sensitivity to MDM2 inhibition.
Ishizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, Zhao R, Heese L, Ma W, Ma MCJ, DiNardo C, Pierce S, Patel KP, Tse A, Davis RE, Rao A, Andreeff M. Predictive gene signatures determine tumor sensitivity to MDM2 inhibition. Cancer Research. 2018;78(10):2721–2731.
Small-molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer.
McClinch K, Avelar RA, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, Zaware N, Gong Y, Brautigan DL, Plymate SR, Sprenger CCT, Oh WK, Levine AC, Kirschenbaum A, Sfakianos JP, Sears R, DiFeo A, Ioannou Y, Ohlmeyer M, Narla G, Galsky MD. Small-molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer. Cancer Research. 2018;78(8):2065–2080.
Assessing bioactivity-exposure profiles of fruit and vegetable extracts in the BioMAP profiling system.
Wetmore BA, Clewell RA, Cholewa B, Parks B, Pendse SN, Black MB, Mansouri K, Haider S, Berg EL, Judson RS, Houck KA, Martin M, Clewell HJ 3rd, Andersen ME, Thomas RS, McMullen PD. Assessing bioactivity-exposure profiles of fruit and vegetable extracts in the BioMAP profiling system. Toxicology in Vitro. 2019;54:41–57.
Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo.
Stevenson AJ, Ager EI, Proctor MA, Škalamera D, Heaton A, Brown D, Gabrielli BG. Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo. Scientific Reports. 2018;8(1).
Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype.
Hirt UA, Waizenegger IC, Schweifer N, Haslinger C, Gerlach D, Braunger J, Weyer-Czernilofsky U, Stadtmüller H, Sapountzis I, Bader G, Zoephel A, Bister B, Baum A, Quant J, Kraut N, Garin-Chesa P, Adolf GR. Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype. Oncogenesis. 2018;7(2):21.
Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing.
Rubin J, Mansoori S, Blom K, Berglund M, Lenhammar L, Andersson C, Loskog A, Fryknäs M, Nygren P, Larsson R. Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing. Oncotarget. 2018;9(56):30805-30813.
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate.
O’Mahony A, John MR, Cho H, Hashizume M, Choy EH. Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate. Journal of Translational Medicine. 2018;16(156).
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.
Thomenius MJ, Totman J, Harvey D, Mitchell LH, Riera TV, Cosmopoulos K, Grassian AR, Klaus C, Foley M, Admirand EA, Jahic H, Majer C, Wigle T, Jacques SL, Gureasko J, Brach D, Lingaraj T, West K, Smith S, Rioux N, Waters NJ, Tang C, Raimondi A, Munchhof M, Mills JE, Ribich S, Porter Scott M, Kuntz KW, Janzen WP, Moyer M, Smith JJ, Chesworth R, Copeland RA, Boriack-Sjodin PA. Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation. PLOS ONE. 2018;13(6):e0197372.
Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability.
Iwai K, Yaguchi M, Nishimura K, Yamamoto Y, Tamura T, Nakata D, Dairiki R, Kawakita Y, Mizojiri R, Ito Y, Asano M, Maezaki H, Nakayama Y, Kaishima M, Hayashi K, Teratani M, Miyakawa S, Iwatani M, Miyamoto M, Klein MG, Lane W, Snell G, Tjhen R, He X, Pulukuri S, Nomura T. Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability. EMBO Molecular Medicine. 2018;10(6).
Mechanisms of skin toxicity associated with metabotropic glutamate receptor 5 negative allosteric modulators.
Shah F, Stepan AF, O’Mahony A, Velichko S, Folias AE, Houle C, Shaffer CL, Marcek J, Whritenour J, Stanton R, Berg EL. Mechanisms of skin toxicity associated with metabotropic glutamate receptor 5 negative allosteric modulators. Cell Chemical Biology. 2017;24(7):858–869.e5.
Phenotypic chemical biology for predicting safety and efficacy.
Berg EL. Phenotypic chemical biology for predicting safety and efficacy. Drug Discovery Today: Technologies. 2017;23:53–60.
Empirical drug discovery: a view from the proteome.
Lee JA, Carragher NO, Berg EL. Empirical drug discovery: a view from the proteome. Drug Discovery Today: Technologies. 2017;23:1–5.
Identification of a chemical probe for family VIII bromodomains through optimization of a fragment hit.
Gerstenberger BS, Trzupek JD, Tallant C, Fedorov O, Filippakopoulos P, Brennan PE, Fedele V, Martin S, Picaud S, Rogers C, Parikh M, Taylor A, Samas B, O’Mahony A, Berg EL, Pallares G, Torrey AD, Treiber DK, Samardjiev IJ, Nasipak BT, Padilla-Benavides T, Wu Q, Imbalzano AN, Nickerson JA, Bunnage ME, Müller S, Knapp S, Owen DR. Identification of a chemical probe for family VIII bromodomains through optimization of a fragment hit. Journal of medicinal chemistry. 2016;59(10):4800–4811.
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.
Hammitzsch A, Tallant C, Fedorov O, O’Mahony A, Brennan PE, Hay DA, Martinez FO, Al-Mossawi MH, de Wit J, Vecellio M, Wells C, Wordsworth P, Müller S, Knapp S, Bowness P. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. PNAS. 2015;112(34):10768–10773.
DMF, but not other fumarates, inhibits NF-κB activity in vitro in an Nrf2-independent manner.
Gillard GO, Collette B, Anderson J, Chao J, Scannevin RH, Huss DJ, Fontenot JD. DMF, but not other fumarates, inhibits NF-κB activity in vitro in an Nrf2-independent manner. Journal of Neuroimmunology. 2015;283:74–85.
Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems—a chemical biology approach for thrombosis-related side effects.
Berg EL, Polokoff MA, O’Mahony A, Nguyen D, Li X. Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems—a chemical biology approach for thrombosis-related side effects. International Journal of Molecular Sciences. 2015;16(1):1008–1029.
Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.
Zhong Y, Dong S, Strattan E, Ren L, Butchar JP, Thornton K, Mishra A, Porcu P, Bradshaw JM, Bisconte A, Owens TD, Verner E, Brameld KA, Funk JO, Hill RJ, Johnson AJ, Dubovsky JA. Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694. Journal of Biological Chemistry. 2015;290(10):5960–5978.
Complex Primary Human Cell Systems for Drug Discovery. In: Human-based Systems for Translational Research.
Berg EL, O’Mahony A. Complex Primary Human Cell Systems for Drug Discovery. In: Human-based Systems for Translational Research. The Royal Society of Chemistry; 2014; p.88–109. Chapter 5; Edited by Robert Coleman.
Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms.
Kleinstreuer NC, Yang J, Berg EL, Knudsen TB, Richard AM, Martin MT, Reif DM, Judson RS, Polokoff M, Dix DJ, Kavlock RJ, Houck KA. Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms. Nature Biotechnology. 2014;32(6):583–591.
Characterization of novel PI3Kδ inhibitors as potential therapeutics for SLE and lupus nephritis in pre-clinical studies.
Haselmayer P, Camps M, Muzerelle M, El Bawab S, Waltzinger C, Bruns L, Abla N, Polokoff MA, Jond-Necand C, Gaudet M, Benoit A, Bertschy Meier D, Martin C, Gretener D, Lombardi MS, Grenningloh R, Ladel C, Petersen JS, Gaillard P, Ji H. Characterization of novel PI3Kδ inhibitors as potential therapeutics for SLE and lupus nephritis in pre-clinical studies. Frontiers in Immunology. 2014;5:233.
Consideration of the cellular microenvironment: physiologically relevant co-culture systems in drug discovery.
Berg EL, Hsu Y-C, Lee JA. Consideration of the cellular microenvironment: physiologically relevant co-culture systems in drug discovery. Advanced Drug Delivery Reviews. 2014;69–70:190–204.
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
Ciceri P, Müller S, O’Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, Lasater EA, Pallares G, Picaud S, Wells C, Martin S, Wodicka LM, Shah NP, Treiber DK, Knapp S. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nature Chemical Biology. 2014;10(4):305–312.
Building predictive models for mechanism-of-action classification from phenotypic assay data sets.
Berg EL, Yang J, Polokoff MA. Building predictive models for mechanism-of-action classification from phenotypic assay data sets. Journal of Biomolecular Screening. 2013;18(10):1260–1269.
Regulation of IL-17A production is distinct from IL-17F in a primary human cell co-culture model of T cell-mediated B cell activation.
Melton AC, Melrose J, Alajoki L, Privat S, Cho H, Brown N, Plavec AM, Nguyen D, Johnston ED, Yang J, Polokoff MA, Plavec I, Berg EL, O’Mahony A. Regulation of IL-17A production is distinct from IL-17F in a primary human cell co-culture model of T cell-mediated B cell activation. PLOS ONE. 2013;8(3):e58966.
A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiation.
Bergamini G, Bell K, Shimamura S, Werner T, Cansfield A, Müller K, Perrin J, Rau C, Ellard K, Hopf C, Doce C, Leggate D, Mangano R, Mathieson T, O'Mahony A, Plavec I, Rharbaoui F, Reinhard F, Savitski MM, Ramsden N, Hirsch E, Drewes G, Rausch O, Bantscheff M, Neubauer G. A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiation. Nature Chemical Biology. 2012;8(6):576–582.
A novel framework for predicting in vivo toxicities from in vitro data using optimal methods for dense and sparse matrix reordering and logistic regression.
DiMaggio PA, Subramani A, Judson RS, Floudas CA. A novel framework for predicting in vivo toxicities from in vitro data using optimal methods for dense and sparse matrix reordering and logistic regression. Toxicological Sciences. 2010;118(1):251–265.
Discovery of dual inhibitors of the immune cell PI3Ks p110δ and p110γ: a prototype for new anti-inflammatory drugs.
Williams O, Houseman BT, Kunkel EJ, Aizenstein B, Hoffman R, Knight ZA, Shokat KM. Discovery of dual inhibitors of the immune cell PI3Ks p110δ and p110γ: a prototype for new anti-inflammatory drugs. Chemistry & Biology. 2010;17(2):123–134.
Chemical target and pathway toxicity mechanisms defined in primary human cell systems.
Berg EL, Yang J, Melrose J, Nguyen D, Privat S, Rosler E, Kunkel EJ, Ekins S. Chemical target and pathway toxicity mechanisms defined in primary human cell systems. Journal of Pharmacological and Toxicological Methods. 2010;61(1):3–15.
Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems.
Houck KA, Dix DJ, Judson RS, Kavlock RJ, Yang J, Berg EL. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. Journal of Biomolecular Screening. 2009;14(9):1054–1066.
Characterization of compound mechanisms and secondary activities by BioMAP analysis.
Berg EL, Kunkel EJ, Hytopoulos E, Plavec I. Characterization of compound mechanisms and secondary activities by BioMAP analysis. Journal of Pharmacological and Toxicological Methods. 2006;53(1):67–74.
Biological complexity and drug discovery: a practical systems biology approach.
Berg EL, Kunkel EJ, Hytopoulos E. Biological complexity and drug discovery: a practical systems biology approach. Systems Biology. 2005;152(4):201–206.
Can cell systems biology rescue drug discovery?
Butcher EC. Can cell systems biology rescue drug discovery? Nature Reviews Drug Discovery. 2005; 4(6):461–467.
Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models.
Kunkel EJ, Plavec I, Nguyen D, Melrose J, Rosler ES, Kao LT, Wang Y, Hytopoulos E, Bishop AC, Bateman R, Shokat KM, Butcher EC, Berg EL. Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models. Assay and Drug Development Technologies. 2004;2(4):431–441.
An integrative biology approach for analysis of drug action in models of human vascular inflammation.
Kunkel EJ, Dea M, Ebens A, Hytopoulos E, Melrose J, Nguyen D, Ota KS, Plavec I, Wang Y, Watson SR, Butcher EC, Berg EL. An integrative biology approach for analysis of drug action in models of human vascular inflammation. FASEB Journal. 2004;18(11):1279–1281.

Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells.
Kramer J, Himmel HM, Lindqvist A, Stoelzle-Feix S, Chaudhary KW, Li D, Bohme GA, Bridgland-Taylor M, Hebeisen S, Fan J, Renganathan M, Imredy J, Humphries E, Brinkwirth N, Strassmaier T, Ohtsuki A, Danker T, Vanoye C, Polonchuk L, Fermini B, Beck Pierson J, Gintant G. Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells. Scientific Reports. 2020 Mar 27;10(1):5627
A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm.
Ridder BJ, Leishman DJ, Bridgland-Taylor M, Samieegohar M, Han X, Wu WW, Randolph A, Tran P, Sheng J, Danker T, Lindqvist A, Konrad D, Hebeisen S, Polonchuk L, Gissinger E, Renganathan M, Koci B, Wei H, Fan J, Levesque P, Kwagh J, Imredy J, Zhai J, Rogers M, Humphries E, Kirby R, Stoelzle-Feix S, Brinkwirth N, Rotordam MG, Becker N, Friis S, Rapedius M, Goetze TA, Strassmaier T, Okeyo G, Kramer J, Kuryshev Y, Wu C, Himmel H, Mirams GR, Strauss DG, Bardenet R, Li Z. A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm. Toxicol Appl Pharmacol. May 1;394. 2020

resource type

Publications & References